Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel

Snoep, 2007, Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis, Am Heart J, 154, 221, 10.1016/j.ahj.2007.04.014 Siller-Matula, 2007, Thienopyridines in cardiovascular disease: focus on clopidogrel resistance, Thromb Haemost, 97, 385, 10.1160/TH06-08-0420 Weerakkody, 2007, Clopidogrel poor responders: an objective definition based on Bayesian classification, Platelets, 18, 428, 10.1080/09537100701206790 Fefer, 2007, Clopidogrel resistance—the cardiologist's perspective, Platelets, 18, 175, 10.1080/09537100601039747 Savi, 2000, Identification and biological activity of the active metabolite of clopidogrel, Thromb Haemost, 84, 891, 10.1055/s-0037-1614133 Pereillo, 2002, Structure and stereochemistry of the active metabolite of clopidogrel, Drug Metab Dispos, 30, 1288, 10.1124/dmd.30.11.1288 Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC Nishio, 2005, Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension, Hypertens Res, 28, 223, 10.1291/hypres.28.223 Watanabe, 2004, Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension, Life Sci, 76, 281, 10.1016/j.lfs.2004.06.022 Katoh, 2000, Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions, Eur J Clin Pharmacol, 55, 843, 10.1007/s002280050706 Cairns, 2008, Clopidogrel resistance: more grist for the mill, J Am Coll Cardiol, 51, 1935, 10.1016/j.jacc.2008.01.051 Gurbel, 2007, Platelet function monitoring in patients with coronary artery disease, J Am Coll Cardiol, 50, 1822, 10.1016/j.jacc.2007.07.051 Manolopoulos, 2008, Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents, Platelets, 19, 134, 10.1080/09537100701708498 Sudo, 2003, Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets, Platelets, 14, 381, 10.1080/09537100310001598819 Judge, 2008, The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses, Platelets, 19, 125, 10.1080/09537100701694144 Bonello, 2007, Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events, J Thromb Haemost, 5, 1630, 10.1111/j.1538-7836.2007.02609.x Bonello, 2008, Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study, J Am Coll Cardiol, 51, 1404, 10.1016/j.jacc.2007.12.044 Kleiman, 2008, Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel?, J Am Coll Cardiol, 51, 1412, 10.1016/j.jacc.2008.02.026 Schwarz, 1999, Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets—definition and detection of ticlopidine/clopidogrel effects, Thromb Haemost, 82, 1145, 10.1055/s-0037-1614344 Jang, 2006, Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion, Eur J Pharm Sci, 28, 405, 10.1016/j.ejps.2006.04.013 Hernandez-Hernandez, 2002, Comparison of two nimodipine formulations in healthy volunteers, J Hum Hypertens, 16, 142, 10.1038/sj.jhh.1001361 Toth, 2006, Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood, Thromb Haemost, 96, 781, 10.1160/TH06-05-0242 Penz, 2007, Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques, Thromb Haemost, 97, 435, 10.1160/TH06-07-0415 Mueller, 2007, Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate(R) analyzer: comparison with two flow cytometric methods, Thromb Res, 121, 249, 10.1016/j.thromres.2007.03.022 Aleil, 2005, Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases, J Thromb Haemost, 3, 85, 10.1111/j.1538-7836.2004.01063.x Blindt, 2007, The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis, Thromb Haemost, 98, 1329, 10.1160/TH07-05-0324 Geiger, 2005, Monitoring of clopidogrel action: comparison of methods, Clin Chem, 51, 957, 10.1373/clinchem.2004.047050 Frere, 2007, ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome, Thromb Haemost, 98, 838, 10.1160/TH07-04-0296 Morel, 2007, Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis, Thromb Haemost, 98, 896, 10.1160/TH07-03-0188 Forbes, 1999, Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist, Semin Thromb Hemost, 25, 55 Markham, 1993, Diltiazem, Drugs Aging, 3, 363, 10.2165/00002512-199303040-00007 Guengerich, 1991, Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4, J Med Chem, 34, 1838, 10.1021/jm00110a012 Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently, Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139 Suh, 2006, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel, CMAJ, 174, 1715, 10.1503/cmaj.060664 Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance, Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9 Neubauer, 2003, Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function—a flow cytometry study, Eur Heart J, 24, 1744, 10.1016/S0195-668X(03)00442-1 Poulsen, 2005, Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors?, Basic Clin Pharmacol Toxicol, 96, 103, 10.1111/j.1742-7843.2005.pto960203.x Muller, 2003, Effects of statins on platelet inhibition by a high loading dose of clopidogrel, Circulation, 108, 2195, 10.1161/01.CIR.0000099507.32936.C0 Tselepis, 2005, Lipophilic statins do not affect the antiplatelet potency of clopidogrel, Platelets, 16, 225, 10.1080/09537100500124525 Mitsios, 2005, The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes, Platelets, 16, 287, 10.1080/09537100400028776 Saw, 2007, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J Am Coll Cardiol, 50, 291, 10.1016/j.jacc.2007.01.097 Angiolillo, 2007, Clopidogrel-statin interaction: myth or reality?, J Am Coll Cardiol, 50, 296, 10.1016/j.jacc.2007.04.041